What's in Celltrion's pipeline?

Celltrion has 71 drugs in our index: 9 marketed, 0 filed, 33 in Phase 3, 4 in Phase 2, 25 in Phase 1.

Which companies overlap with Celltrion's portfolio?

Top competitors by shared drug class: Sandoz, Amgen, Pfizer, AMGEN INC, Roche.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/celltrion.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-14 · How we verify

Celltrion — Portfolio Competitive Intelligence Brief

Celltrion (068270.KS) pipeline: 9 marketed, 0 filed, 33 Phase 3, 4 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

068270.KS (KRX) 9 marketed 0 filed 33 Phase 3 4 Phase 2 25 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area	First approval
Regkirona	REGDANVIMAB	marketed			Infectious Disease	2021-01-01
TRUXIMA	RITUXIMAB-ABBS	marketed	CD20-directed Cytolytic Antibody [EPC]		Other
AVTOZMA	TOCILIZUMAB-ANOH	marketed	Interleukin-6 Receptor Antagonist [EPC]		Other
Placebo Auto-Injector	Placebo Auto-Injector	marketed
YUFLYMA	ADALIMUMAB-AATY	marketed			Other
STEQEYMA	USTEKINUMAB-STBA	marketed	Interleukin-12 Antagonist [EPC]	p40 protein subunit of IL-12 and IL-23	Other
EYDENZELT	AFLIBERCEPT-BOAV	marketed			Other
HERZUMA	TRASTUZUMAB-PKRB	marketed	HER2/neu Receptor Antagonist [EPC]		Other
VEGZELMA	BEVACIZUMAB-ADCD	marketed	Vascular Endothelial Growth Factor Inhibitor [EPC]		Other
CT-P17 SC AI (adalimumab)	CT-P17 SC AI (adalimumab)	phase 3	TNF-α inhibitor (monoclonal antibody biosimilar)	TNF-α (tumor necrosis factor-alpha)	Immunology
AZM X mg + AML Y mg	AZM X mg + AML Y mg	phase 3	Angiotensin II receptor blocker + Calcium channel blocker combination	AT1 receptor (azilsartan); L-type calcium channel (amlodipine)	Cardiovascular
CT-P39	CT-P39	phase 3	PD-L1 inhibitor; monoclonal antibody	PD-L1 (Programmed Death Ligand 1)	Oncology

Therapeutic area mix

Oncology · 14
Immunology · 9
Other · 7
Immunology / Rheumatology · 3
Infectious Disease · 2
Infectious diseases · 1
Osteoporosis · 1
Immunology / Rheumatology / Gastroenterology · 1
Immunology / Allergy · 1
Immunology / Dermatology / Rheumatology · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Sandoz · 6 shared drug classes
Amgen · 5 shared drug classes
Pfizer · 5 shared drug classes
AMGEN INC · 4 shared drug classes
Roche · 4 shared drug classes
Merck Sharp & Dohme LLC · 4 shared drug classes
Mylan Inc. · 3 shared drug classes
Centocor, Inc. · 3 shared drug classes

Subscribe to ongoing alerts

Every new pipeline event for Celltrion:

Cite this brief

Drug Landscape (2026). Celltrion — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/celltrion. Accessed 2026-05-14.